Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Bladder cancer in 2014

From the genomic frontier to immunotherapeutics

Publications in 2014 advanced our therapeutic armamentarium for bladder cancer. Molecular characterization might propel us into an era of targeted therapy, and immunotherapeutics might expand our options for patients with metastatic disease. We were also reminded that outcomes are inextricably linked to the quality of the transurethral resections we perform.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315–322 (2014).

  2. Wagle, N. et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov. 4, 546–553 (2014).

    Article  Google Scholar 

  3. Sylvester, R. J. et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 49, 466–477; discussion 623–627 (2006).

    Article  Google Scholar 

  4. James, A. C. & Gore, J. L. The costs of non-muscle invasive bladder cancer. Urol. Clin. North Am. 40, 261–269 (2013).

    Article  Google Scholar 

  5. Solsona, E. et al. Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial. Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2014.09.026.

  6. Inman, B. A. et al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer 109, 1499–1505 (2007).

    Article  CAS  Google Scholar 

  7. Powles, T. et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515, 558–562 (2014).

    Article  CAS  Google Scholar 

  8. Mahoney, K. M. & Atkins, M. B. Prognostic and predictive markers for the new immunotherapies. Oncology (Williston Park) 28, 202335 (2014).

    Google Scholar 

  9. Gore, J. L. et al. Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a Surveillance, Epidemiology, and End Results-Medicare analysis. Cancer 115, 988–996 (2009).

    Article  Google Scholar 

  10. Chamie, K. et al. Quality of diagnostic staging in patients with bladder cancer: a process–outcomes link. Cancer http://dx.doi.org/10.1002/cncr.29071.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Karim Chamie.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lenis, A., Chamie, K. From the genomic frontier to immunotherapeutics. Nat Rev Urol 12, 74–76 (2015). https://doi.org/10.1038/nrurol.2014.369

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2014.369

This article is cited by

Search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer